LONDON and RALEIGH, NC, June 06, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces that it will host an in-person KOL event for analysts and investors on Thursday, June 16, 2022, at 8:00 a.m. ET, in New York.
Verona Pharma’s KOL event will include executive presentations and a discussion with key opinion leaders on the COPD treatment landscape, including unmet need, the treatment paradigm and how ensifentrine could potentially help solve these problems. Key opinion leaders, Igor Bajaktarevic, MD, Medical Director, COPD Program, UCLA Division of Pulmonary and Critical Care Medicine and Jill Ohar, MD, Professor of Medicine, Wake Forest University, will share their insights.
Verona Pharma expects to announce leading Phase 3 ENHANCE data in COPD in Q3 2022 and towards the end of 2022.
A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company specializing in respiratory diseases. The Company is evaluating nebulized ensifentrine in its ENHANCE Phase 3 clinical program (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for the maintenance treatment of COPD. Main data is expected in the third quarter of 2022 and towards the end of 2022.
If successfully developed and approved, ensifentrine has the potential to be the first therapy for the treatment of respiratory disease that combines bronchodilator and anti-inflammatory activities in a single compound. Two additional ensifentrine formulations are in Phase 2 development for the treatment of COPD: the dry powder inhaler (“DPI”) and the pressurized metered-dose inhaler (“pMDI”). Ensifentrin has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
All statements in this press release that do not relate to historical facts should be considered forward-looking statements, including, but not limited to, statements regarding the development of ensifentrine and the progress and timeline of clinical trials and data, the potential for ensifentrine to be a first-in-class inhibitor of phosphodiesterases 3 and 4 and to be the first therapy for the treatment of respiratory diseases to combine bronchodilator and anti-inflammatory effects in a single compound, and the potential of ensifentrine in the treatment of COPD, cystic fibrosis, asthma and other respiratory diseases, as well as the potential of DPI and pMDI formulations of ensifentrine.
For more information, please contact:
|Verona Pharma plc||Such. USA: +1-833-417-0262
Such. UK: +44 (0)203 283 4200
|Victoria Stewart, Director of Investor Relations and Communications||[email protected]|
(Requests from US Investors)
|Kimberly Minarovich/Michael Barron|
|Optimal strategic communications
(International media and requests from European investors)
|Tel: +44 (0)203 950 9144
|Mary Clark / Rebecca Noonan / Zoe Bolt|